Prediction of Epidermal Growth Factor Receptor Mutation Subtypes in Non–Small Cell Lung Cancer From Hematoxylin and Eosin–Stained Slides Using Deep Learning
- 12 June 2024
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 104 (8) , 102094
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2021YFF1201000)
- National Natural Science Foundation of China (81702954, 61771031, 61901018, 61906058, 62171007)
- Ministry of Education of the People's Republic of China (2022jsz805)
- Army Medical University
- Natural Science Foundation of Anhui Province (2208085MH250, 2308085MH272)
- Fundamental Research Funds for the Central Universities (JZ2022HGTB0285, YWF-23-Q-1075)
This publication has 36 references indexed in Scilit:
- Predicting oncogene mutations of lung cancer using deep learning and histopathologic features on whole-slide imagesTranslational Oncology, 2022
- Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practiceLung Cancer, 2022
- Introduction to 2021 WHO Classification of Thoracic TumorsJournal of Thoracic Oncology, 2022
- Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World UseJournal of Thoracic Oncology, 2020
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialThe Lancet Oncology, 2016
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancersLung Cancer, 2015
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyThe Lancet Oncology, 2014
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Should we be surprised at the paucity of response to EGFR inhibitors?The Lancet Oncology, 2009
- LKB1 tumor suppressor protein: PARtaker in cell polarityTrends in Cell Biology, 2004